{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:56:15Z","timestamp":1793908575225,"version":"4.8.0"},"reference-count":108,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"vor","delay-in-days":1514,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s13311-019-00750-3","type":"journal-article","created":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T12:23:32Z","timestamp":1561465412000},"page":"685-702","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":134,"title":["Autoimmune Epilepsy"],"prefix":"10.1016","volume":"16","author":[{"given":"Khalil S.","family":"Husari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divyanshu","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1007\/s13311-019-00750-3_bib1","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1001\/jamaneurol.2014.188","article-title":"Population-level evidence for an autoimmune etiology of epilepsy","volume":"71","author":"Ong","year":"2014","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1007\/s13311-019-00750-3_bib2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1684\/epd.2018.0957","article-title":"The 2017 ILAE classification of seizure types and the epilepsies: what do people with epilepsy and their caregivers need to know?","volume":"20","author":"Brodie","year":"2018","journal-title":"Epileptic Disord"},{"issue":"2","key":"10.1007\/s13311-019-00750-3_bib3","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/epi.14649","article-title":"Antibody Prevalence in Epilepsy and Encephalopathy score: Increased specificity and applicability","volume":"60","author":"Dubey","year":"2019","journal-title":"Epilepsia"},{"issue":"4","key":"10.1007\/s13311-019-00750-3_bib4","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/jamaneurol.2016.5429","article-title":"Neurological Autoantibody Prevalence in Epilepsy of Unknown Etiology","volume":"74","author":"Dubey","year":"2017","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1007\/s13311-019-00750-3_bib5","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1007\/s13311-019-00750-3_bib6","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/B978-0-444-52891-9.00054-3","article-title":"Rasmussen encephalitis","volume":"111","author":"Granata","year":"2013","journal-title":"Handb Clin Neurol"},{"key":"10.1007\/s13311-019-00750-3_bib7","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/B978-0-444-63432-0.00013-X","article-title":"Autoimmune epilepsy","volume":"133","author":"Britton","year":"2016","journal-title":"Handb Clin Neurol"},{"issue":"9","key":"10.1007\/s13311-019-00750-3_bib8","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1056\/NEJMra1708712","article-title":"Antibody-Mediated Encephalitis","volume":"378","author":"Dalmau","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1007\/s13311-019-00750-3_bib9","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nbt.1856","article-title":"Autoantigen discovery with a synthetic human peptidome","volume":"29","author":"Larman","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1007\/s13311-019-00750-3_bib10","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.3389\/fimmu.2018.01447","article-title":"A Spectrum of Neural Autoantigens, Newly Identified by Histo-Immunoprecipitation, Mass Spectrometry, and Recombinant Cell-Based Indirect Immunofluorescence","volume":"9","author":"Scharf","year":"2018","journal-title":"Front Immunol"},{"issue":"3","key":"10.1007\/s13311-019-00750-3_bib11","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/WCO.0000000000000198","article-title":"A tale of two approaches: how metagenomics and proteomics are shaping the future of encephalitis diagnostics","volume":"28","author":"Schubert","year":"2015","journal-title":"Curr Opin Neurol"},{"issue":"5","key":"10.1007\/s13311-019-00750-3_bib12","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.chembiol.2013.04.009","article-title":"Recent advances in microarray technologies for proteomics","volume":"20","author":"Sun","year":"2013","journal-title":"Chem Biol"},{"issue":"18","key":"10.1007\/s13311-019-00750-3_bib13","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1212\/WNL.0000000000000383","article-title":"Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy","volume":"82","author":"Toledano","year":"2014","journal-title":"Neurology"},{"issue":"1","key":"10.1007\/s13311-019-00750-3_bib14","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ana.25131","article-title":"Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis","volume":"83","author":"Dubey","year":"2018","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1007\/s13311-019-00750-3_bib15","first-page":"80","article-title":"Clinical presentation of autoimmune and viral encephalitides","volume":"24","author":"Dubey","year":"2018","journal-title":"Curr Opin Crit Care"},{"issue":"8","key":"10.1007\/s13311-019-00750-3_bib16","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1136\/jnnp.2003.034447","article-title":"Recommended diagnostic criteria for paraneoplastic neurological syndromes","volume":"75","author":"Graus","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"10.1007\/s13311-019-00750-3_bib17","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1111\/epi.13797","article-title":"Predictive models in the diagnosis and treatment of autoimmune epilepsy","volume":"58","author":"Dubey","year":"2017","journal-title":"Epilepsia"},{"issue":"6","key":"10.1007\/s13311-019-00750-3_bib18","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/epi.12127","article-title":"Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy","volume":"54","author":"Brenner","year":"2013","journal-title":"Epilepsia"},{"key":"10.1007\/s13311-019-00750-3_bib19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/B978-0-12-802973-2.00010-0","article-title":"Epidemiology of epilepsy","volume":"138","author":"Abramovici","year":"2016","journal-title":"Handb Clin Neurol"},{"issue":"5","key":"10.1007\/s13311-019-00750-3_bib20","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/epi.13356","article-title":"Neuronal antibodies in pediatric epilepsy: Clinical features and long-term outcomes of a historical cohort not treated with immunotherapy","volume":"57","author":"Wright","year":"2016","journal-title":"Epilepsia"},{"issue":"12","key":"10.1007\/s13311-019-00750-3_bib21","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1111\/epi.12405","article-title":"Autoantibodies to neuronal antigens in children with new-onset seizures classified according to the revised ILAE organization of seizures and epilepsies","volume":"54","author":"Suleiman","year":"2013","journal-title":"Epilepsia"},{"issue":"Suppl 3","key":"10.1007\/s13311-019-00750-3_bib22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/epi.13784","article-title":"Innate and adaptive immunity in human epilepsies","volume":"58","author":"Bauer","year":"2017","journal-title":"Epilepsia"},{"issue":"1","key":"10.1007\/s13311-019-00750-3_bib23","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1128\/CMR.19.1.80-94.2006","article-title":"Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease","volume":"19","author":"Fujinami","year":"2006","journal-title":"Clin Microbiol Rev"},{"issue":"9","key":"10.1007\/s13311-019-00750-3_bib24","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S1474-4422(18)30244-8","article-title":"Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis","volume":"17","author":"Armangue","year":"2018","journal-title":"Lancet Neurol"},{"issue":"46","key":"10.1007\/s13311-019-00750-3_bib25","doi-asserted-by":"crossref","first-page":"18161","DOI":"10.1523\/JNEUROSCI.3506-13.2013","article-title":"Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors","volume":"33","author":"Ohkawa","year":"2013","journal-title":"J Neurosci"},{"issue":"11","key":"10.1007\/s13311-019-00750-3_bib26","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1097\/WNR.0000000000001055","article-title":"Effect of LGI1 antibody-positive IgG on hippocampal neuron survival: a preliminary study","volume":"29","author":"Aysit-Altuncu","year":"2018","journal-title":"Neuroreport"},{"issue":"17","key":"10.1007\/s13311-019-00750-3_bib27","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1523\/JNEUROSCI.0167-10.2010","article-title":"Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis","volume":"30","author":"Hughes","year":"2010","journal-title":"J Neurosci"},{"issue":"2","key":"10.1007\/s13311-019-00750-3_bib28","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1474-4422(13)70282-5","article-title":"Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study","volume":"13","author":"Gresa-Arribas","year":"2014","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1007\/s13311-019-00750-3_bib29","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/3315","article-title":"Tumor-specific killer cells in paraneoplastic cerebellar degeneration","volume":"4","author":"Albert","year":"1998","journal-title":"Nat Med"},{"key":"10.1007\/s13311-019-00750-3_bib30","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ana.24881","article-title":"Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: Analysis of 102 patients.","volume":"81","author":"Flanagan","year":"2017","journal-title":"Ann Neurol."},{"issue":"5","key":"10.1007\/s13311-019-00750-3_bib31","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1528-1167.2009.02325.x","article-title":"Clinical significance of glutamic acid decarboxylase antibodies in patients with epilepsy","volume":"51","author":"Liimatainen","year":"2010","journal-title":"Epilepsia"},{"key":"10.1007\/s13311-019-00750-3_bib32","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.yebeh.2018.01.021","article-title":"Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy","volume":"80","author":"Daif","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1007\/s13311-019-00750-3_bib33","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jneuroim.2018.07.009","article-title":"Predictors of neural-specific autoantibodies and immunotherapy response in patients with cognitive dysfunction","volume":"323","author":"Dubey","year":"2018","journal-title":"J Neuroimmunol"},{"issue":"2","key":"10.1007\/s13311-019-00750-3_bib34","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1007\/s13311-019-00750-3_bib35","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1152\/physrev.00010.2016","article-title":"Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System","volume":"97","author":"Dalmau","year":"2017","journal-title":"Physiol Rev"},{"issue":"3","key":"10.1007\/s13311-019-00750-3_bib36","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1055\/s-0038-1660860","article-title":"Autoimmune Epilepsy: The Evolving Science of Neural Autoimmunity and Its Impact on Epilepsy Management","volume":"38","author":"Quek","year":"2018","journal-title":"Semin Neurol"},{"issue":"1","key":"10.1007\/s13311-019-00750-3_bib37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/ana.21050","article-title":"Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma","volume":"61","author":"Dalmau","year":"2007","journal-title":"Ann Neurol"},{"issue":"12","key":"10.1007\/s13311-019-00750-3_bib38","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1212\/WNL.0b013e3182a4a49c","article-title":"Late-onset anti-NMDA receptor encephalitis","volume":"81","author":"Titulaer","year":"2013","journal-title":"Neurology"},{"issue":"4","key":"10.1007\/s13311-019-00750-3_bib39","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/ana.25216","article-title":"Genetic predisposition in anti-LGI1 and anti-NMDA receptor encephalitis","volume":"83","author":"Mueller","year":"2018","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1007\/s13311-019-00750-3_bib40","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/ana.25310","article-title":"LGI1 and CASPR2 Neurological Autoimmunity in Children","volume":"84","author":"Sebastian Lopez-Chiriboga","year":"2018","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1007\/s13311-019-00750-3_bib41","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/ana.22307","article-title":"Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis","volume":"69","author":"Irani","year":"2011","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1007\/s13311-019-00750-3_bib42","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ana.24979","article-title":"Expanded phenotypes and outcomes among 256 LGI1\/CASPR2-IgG-positive patients","volume":"82","author":"Gadoth","year":"2017","journal-title":"Ann Neurol"},{"issue":"17","key":"10.1007\/s13311-019-00750-3_bib43","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1212\/WNL.0000000000003300","article-title":"The relevance of VGKC positivity in the absence of LGI1 and Caspr2 antibodies","volume":"87","author":"Lilleker","year":"2016","journal-title":"Neurology"},{"issue":"18","key":"10.1007\/s13311-019-00750-3_bib44","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1212\/WNL.0000000000002637","article-title":"The relevance of VGKC positivity in the absence of LGI1 and Caspr2 antibodies","volume":"86","author":"van Sonderen","year":"2016","journal-title":"Neurology"},{"issue":"4","key":"10.1007\/s13311-019-00750-3_bib45","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/ana.21589","article-title":"AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location","volume":"65","author":"Lai","year":"2009","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1007\/s13311-019-00750-3_bib46","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.neuron.2018.07.048","article-title":"Human Autoantibodies against the AMPA Receptor Subunit GluA2 Induce Receptor Reorganization and Memory Dysfunction","volume":"100","author":"Haselmann","year":"2018","journal-title":"Neuron"},{"issue":"24","key":"10.1007\/s13311-019-00750-3_bib47","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1212\/WNL.0000000000001682","article-title":"Encephalitis and AMPA receptor antibodies: Novel findings in a case series of 22 patients","volume":"84","author":"Hoftberger","year":"2015","journal-title":"Neurology"},{"issue":"10","key":"10.1007\/s13311-019-00750-3_bib48","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1001\/jamaneurol.2015.1715","article-title":"Clinical Spectrum of Encephalitis Associated With Antibodies Against the alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid Receptor: Case Series and Review of the Literature","volume":"72","author":"Joubert","year":"2015","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1007\/s13311-019-00750-3_bib49","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/ana.23756","article-title":"Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels","volume":"73","author":"Boronat","year":"2013","journal-title":"Ann Neurol"},{"issue":"8276","key":"10.1007\/s13311-019-00750-3_bib50","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/S0140-6736(82)91887-6","article-title":"The Ophelia syndrome: memory loss in Hodgkin's disease","volume":"1","author":"Carr","year":"1982","journal-title":"Lancet"},{"issue":"18","key":"10.1007\/s13311-019-00750-3_bib51","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1212\/WNL.0b013e3182364a44","article-title":"Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome","volume":"77","author":"Lancaster","year":"2011","journal-title":"Neurology"},{"issue":"22","key":"10.1007\/s13311-019-00750-3_bib52","doi-asserted-by":"crossref","first-page":"e1964","DOI":"10.1212\/WNL.0000000000005614","article-title":"Encephalitis with mGluR5 antibodies: Symptoms and antibody effects","volume":"90","author":"Spatola","year":"2018","journal-title":"Neurology"},{"issue":"9","key":"10.1007\/s13311-019-00750-3_bib53","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.4065\/81.9.1207","article-title":"Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction","volume":"81","author":"Pittock","year":"2006","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1007\/s13311-019-00750-3_bib54","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/WNL.55.1.46","article-title":"Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy","volume":"55","author":"Peltola","year":"2000","journal-title":"Neurology"},{"issue":"8","key":"10.1007\/s13311-019-00750-3_bib55","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.seizure.2014.04.009","article-title":"Glutamic acid decarboxylase (GAD) antibodies in epilepsy: diagnostic yield and therapeutic implications","volume":"23","author":"Lilleker","year":"2014","journal-title":"Seizure"},{"issue":"7","key":"10.1007\/s13311-019-00750-3_bib56","first-page":"2042","article-title":"Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells","volume":"119","author":"Roberts","year":"2009","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1007\/s13311-019-00750-3_bib57","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.eplepsyres.2011.04.006","article-title":"Extratemporal EEG and MRI findings in ANNA-1 (anti-Hu) encephalitis","volume":"95","author":"Rudzinski","year":"2011","journal-title":"Epilepsy Res"},{"issue":"5","key":"10.1007\/s13311-019-00750-3_bib58","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ana.10518","article-title":"Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments","volume":"53","author":"Pittock","year":"2003","journal-title":"Ann Neurol"},{"issue":"Pt 8","key":"10.1007\/s13311-019-00750-3_bib59","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1093\/brain\/awh203","article-title":"Clinical analysis of anti-Ma2-associated encephalitis","volume":"127","author":"Dalmau","year":"2004","journal-title":"Brain"},{"issue":"23","key":"10.1007\/s13311-019-00750-3_bib60","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1056\/NEJM199906103402303","article-title":"A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer","volume":"340","author":"Voltz","year":"1999","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1007\/s13311-019-00750-3_bib61","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/1531-8249(20010201)49:2<146::AID-ANA34>3.0.CO;2-E","article-title":"CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity","volume":"49","author":"Yu","year":"2001","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1007\/s13311-019-00750-3_bib62","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1212\/WNL.0000000000004803","article-title":"Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases","volume":"90","author":"Dubey","year":"2018","journal-title":"Neurology"},{"issue":"5","key":"10.1007\/s13311-019-00750-3_bib63","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/ana.10178","article-title":"Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma","volume":"51","author":"Vernino","year":"2002","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1007\/s13311-019-00750-3_bib64","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/archneurol.2011.2985","article-title":"Autoimmune epilepsy: clinical characteristics and response to immunotherapy","volume":"69","author":"Quek","year":"2012","journal-title":"Arch Neurol"},{"issue":"Pt 3","key":"10.1007\/s13311-019-00750-3_bib65","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/brain\/awh415","article-title":"Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement","volume":"128","author":"Bien","year":"2005","journal-title":"Brain"},{"issue":"9","key":"10.1007\/s13311-019-00750-3_bib66","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1111\/j.1528-1167.2012.03565.x","article-title":"Evolution of the EEG in children with Rasmussen's syndrome","volume":"53","author":"Longaretti","year":"2012","journal-title":"Epilepsia"},{"issue":"3","key":"10.1007\/s13311-019-00750-3_bib67","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/epi.12042","article-title":"Rasmussen encephalitis: incidence and course under randomized therapy with tacrolimus or intravenous immunoglobulins","volume":"54","author":"Bien","year":"2013","journal-title":"Epilepsia"},{"issue":"2 Pt 1","key":"10.1007\/s13311-019-00750-3_bib68","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1542\/peds.100.2.163","article-title":"Why would you remove half a brain? The outcome of 58 children after hemispherectomy-the Johns Hopkins experience: 1968 to 1996","volume":"100","author":"Vining","year":"1997","journal-title":"Pediatrics"},{"issue":"18","key":"10.1007\/s13311-019-00750-3_bib69","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1212\/WNL.0000000000001940","article-title":"New-onset refractory status epilepticus: Etiology, clinical features, and outcome","volume":"85","author":"Gaspard","year":"2015","journal-title":"Neurology"},{"issue":"4","key":"10.1007\/s13311-019-00750-3_bib70","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/epi.14022","article-title":"New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES): State of the art and perspectives","volume":"59","author":"Gaspard","year":"2018","journal-title":"Epilepsia"},{"issue":"5","key":"10.1007\/s13311-019-00750-3_bib71","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/WNP.0b013e3182a73d47","article-title":"Electroencephalography of autoimmune limbic encephalopathy","volume":"30","author":"Kaplan","year":"2013","journal-title":"J Clin Neurophysiol"},{"issue":"11","key":"10.1007\/s13311-019-00750-3_bib72","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1212\/WNL.0b013e3182698cd8","article-title":"Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis","volume":"79","author":"Schmitt","year":"2012","journal-title":"Neurology"},{"issue":"4","key":"10.1007\/s13311-019-00750-3_bib73","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1177\/1550059417693168","article-title":"Delta Brush Pattern Is Not Unique to NMDAR Encephalitis: Evaluation of Two Independent Long-Term EEG Cohorts","volume":"49","author":"Baykan","year":"2018","journal-title":"Clin EEG Neurosci"},{"key":"10.1007\/s13311-019-00750-3_bib74","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.seizure.2017.05.017","article-title":"LGI1-antibody encephalitis is characterised by frequent, multifocal clinical and subclinical seizures","volume":"50","author":"Aurangzeb","year":"2017","journal-title":"Seizure"},{"issue":"4","key":"10.1007\/s13311-019-00750-3_bib75","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol"},{"issue":"14","key":"10.1007\/s13311-019-00750-3_bib76","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1212\/WNL.0000000000004541","article-title":"Antibody-associated CNS syndromes without signs of inflammation in the elderly","volume":"89","author":"Escudero","year":"2017","journal-title":"Neurology"},{"key":"10.1007\/s13311-019-00750-3_bib77","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jneuroim.2015.08.014","article-title":"The spectrum of autoimmune encephalopathies","volume":"287","author":"Dubey","year":"2015","journal-title":"J Neuroimmunol"},{"issue":"9","key":"10.1007\/s13311-019-00750-3_bib78","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1111\/epi.13471","article-title":"Suspected new-onset autoimmune temporal lobe epilepsy with amygdala enlargement","volume":"57","author":"Malter","year":"2016","journal-title":"Epilepsia"},{"issue":"2","key":"10.1007\/s13311-019-00750-3_bib79","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/ana.23932","article-title":"Functional and structural brain changes in anti-N-methyl-D-aspartate receptor encephalitis","volume":"74","author":"Finke","year":"2013","journal-title":"Ann Neurol"},{"issue":"8","key":"10.1007\/s13311-019-00750-3_bib80","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.2967\/jnumed.116.184333","article-title":"Diagnostic Value of (18)F-FDG PET\/CT Versus MRI in the Setting of Antibody-Specific Autoimmune Encephalitis","volume":"58","author":"Solnes","year":"2017","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1007\/s13311-019-00750-3_bib81","doi-asserted-by":"crossref","first-page":"e413","DOI":"10.1212\/NXI.0000000000000413","article-title":"Decreased occipital lobe metabolism by FDG-PET\/CT: An anti-NMDA receptor encephalitis biomarker","volume":"5","author":"Probasco","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"10.1007\/s13311-019-00750-3_bib82","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/brb3.14","article-title":"Perfusion IMP-SPECT shows reversible abnormalities in GABA(B) receptor antibody associated encephalitis with normal MRI","volume":"1","author":"Ohta","year":"2011","journal-title":"Brain Behav"},{"issue":"1093","key":"10.1007\/s13311-019-00750-3_bib83","doi-asserted-by":"crossref","first-page":"20170869","DOI":"10.1259\/bjr.20170869","article-title":"Autoimmune epilepsy: findings on MRI and FDG-PET","volume":"92","author":"Guerin","year":"2019","journal-title":"Br J Radiol"},{"key":"10.1007\/s13311-019-00750-3_bib84","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.neuroscience.2015.05.037","article-title":"Imaging of autoimmune encephalitis--Relevance for clinical practice and hippocampal function","volume":"309","author":"Heine","year":"2015","journal-title":"Neuroscience"},{"key":"10.1007\/s13311-019-00750-3_bib85","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/B978-0-444-63432-0.00011-6","article-title":"Voltage-gated potassium channel-complex autoimmunity and associated clinical syndromes","volume":"133","author":"Irani","year":"2016","journal-title":"Handb Clin Neurol"},{"issue":"6","key":"10.1007\/s13311-019-00750-3_bib86","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1212\/NXI.0000000000000161","article-title":"Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures","volume":"2","author":"Flanagan","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1\u20132","key":"10.1007\/s13311-019-00750-3_bib87","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jneuroim.2013.10.005","article-title":"VGKC-complex\/LGI1-antibody encephalitis: clinical manifestations and response to immunotherapy","volume":"265","author":"Shin","year":"2013","journal-title":"J Neuroimmunol"},{"issue":"3","key":"10.1007\/s13311-019-00750-3_bib88","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00234-018-1976-6","article-title":"MRI findings in glutamic acid decarboxylase associated autoimmune epilepsy","volume":"60","author":"Fredriksen","year":"2018","journal-title":"Neuroradiology"},{"issue":"11","key":"10.1007\/s13311-019-00750-3_bib89","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1212\/WNL.0000000000003713","article-title":"Investigations in GABAA receptor antibody-associated encephalitis","volume":"88","author":"Spatola","year":"2017","journal-title":"Neurology"},{"issue":"9","key":"10.1007\/s13311-019-00750-3_bib90","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1136\/jnnp-2014-308814","article-title":"Limbic encephalitis due to GABAB and AMPA receptor antibodies: a case series","volume":"86","author":"Dogan Onugoren","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"17","key":"10.1007\/s13311-019-00750-3_bib91","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1212\/WNL.0b013e3182a9585f","article-title":"Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients","volume":"81","author":"Hoftberger","year":"2013","journal-title":"Neurology"},{"issue":"6","key":"10.1007\/s13311-019-00750-3_bib92","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1212\/WNL.0000000000003586","article-title":"Characteristics in limbic encephalitis with anti-adenylate kinase 5 autoantibodies","volume":"88","author":"Do","year":"2017","journal-title":"Neurology"},{"key":"10.1007\/s13311-019-00750-3_bib93","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/B978-0-444-63432-0.00010-4","article-title":"Paraneoplastic and idiopathic autoimmune neurologic disorders: approach to diagnosis and treatment","volume":"133","author":"Pittock","year":"2016","journal-title":"Handb Clin Neurol"},{"issue":"Pt 10","key":"10.1007\/s13311-019-00750-3_bib94","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1093\/brain\/awt212","article-title":"Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype","volume":"136","author":"Irani","year":"2013","journal-title":"Brain"},{"issue":"1","key":"10.1007\/s13311-019-00750-3_bib95","doi-asserted-by":"crossref","first-page":"e0146455","DOI":"10.1371\/journal.pone.0146455","article-title":"Effect of Immunotherapy on Seizure Outcome in Patients with Autoimmune Encephalitis: A Prospective Observational Registry Study","volume":"11","author":"Byun","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1007\/s13311-019-00750-3_bib96","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/brain\/awx323","article-title":"The importance of early immunotherapy in patients with faciobrachial dystonic seizures","volume":"141","author":"Thompson","year":"2018","journal-title":"Brain"},{"issue":"4","key":"10.1007\/s13311-019-00750-3_bib97","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/WNL.0000000000003536","article-title":"Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis","volume":"88","author":"Scheibe","year":"2017","journal-title":"Neurology"},{"issue":"5","key":"10.1007\/s13311-019-00750-3_bib98","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/intimm\/dxq030","article-title":"IL-6: from its discovery to clinical applications","volume":"22","author":"Kishimoto","year":"2010","journal-title":"Int Immunol"},{"issue":"22","key":"10.1007\/s13311-019-00750-3_bib99","doi-asserted-by":"crossref","first-page":"221101","DOI":"10.1103\/PhysRevLett.118.221101","article-title":"GW170104: Observation of a 50-Solar-Mass Binary Black Hole Coalescence at Redshift 0.2","volume":"118","author":"Abbott","year":"2017","journal-title":"Phys Rev Lett"},{"issue":"6","key":"10.1007\/s13311-019-00750-3_bib100","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/ana.25374","article-title":"Tocilizumab treatment for new onset refractory status epilepticus","volume":"84","author":"Jun","year":"2018","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1007\/s13311-019-00750-3_bib101","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s13311-016-0442-6","article-title":"Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study","volume":"13","author":"Lee","year":"2016","journal-title":"Neurotherapeutics"},{"issue":"1 Epilepsy","key":"10.1007\/s13311-019-00750-3_bib102","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1212\/CON.0000000000000289","article-title":"Antiepileptic Drugs","volume":"22","author":"Abou-Khalil","year":"2016","journal-title":"Continuum (Minneap Minn)"},{"issue":"4","key":"10.1007\/s13311-019-00750-3_bib103","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1212\/NXI.0000000000000353","article-title":"Antiepileptic drug therapy in patients with autoimmune epilepsy","volume":"4","author":"Feyissa","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"Suppl 3","key":"10.1007\/s13311-019-00750-3_bib104","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1528-1167.2011.03035.x","article-title":"Antiepileptic drugs and the immune system","volume":"52","author":"Beghi","year":"2011","journal-title":"Epilepsia"},{"key":"10.1007\/s13311-019-00750-3_bib105","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.eplepsyres.2016.12.010","article-title":"Epilepsy surgery in drug resistant temporal lobe epilepsy associated with neuronal antibodies","volume":"129","author":"Carreno","year":"2017","journal-title":"Epilepsy Res"},{"key":"10.1007\/s13311-019-00750-3_bib106","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.seizure.2015.05.017","article-title":"Treatment of immune-mediated temporal lobe epilepsy with GAD antibodies","volume":"30","author":"Malter","year":"2015","journal-title":"Seizure"},{"issue":"5","key":"10.1007\/s13311-019-00750-3_bib107","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/acn3.561","article-title":"Elevated LGI1-IgG CSF index predicts worse neurological outcome","volume":"5","author":"Gadoth","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"10.1007\/s13311-019-00750-3_bib108","doi-asserted-by":"crossref","first-page":"e244","DOI":"10.1212\/WNL.0000000000006783","article-title":"A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis","volume":"92","author":"Balu","year":"2019","journal-title":"Neurology"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-019-00750-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-019-00750-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923018147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923018147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-019-00750-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:15:35Z","timestamp":1761808535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923018147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":108,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S1878747923018147"],"URL":"https:\/\/doi.org\/10.1007\/s13311-019-00750-3","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoimmune Epilepsy","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-019-00750-3","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}